Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine

European Journal of Clinical Pharmacology

Volumn 59, Issue 5-6, 2003, Pages 401-406

  Lindh, Jonatan D ^a   Annas, Anita ^a   Meurling, Lennart ^a   Dahl, Marja Liisa ^b   Al Shurbaji, Ayman ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cytochrome P450; Drug interactions; Venlafaxine

Indexed keywords

CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEBRISOQUINE; DESVENLAFAXINE; DRUG METABOLITE; KETOCONAZOLE; VENLAFAXINE;

ACCOMMODATION; ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG URINE LEVEL; FATIGUE; FEMALE; GENOTYPE; HEALTH STATUS; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; OPEN STUDY; PHENOTYPE; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; VISUAL DISORDER; VOLUNTEER; VOMITING; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; AREA UNDER CURVE; CYCLOHEXANOLS; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DEBRISOQUIN; DRUG INTERACTIONS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HALF-LIFE; HUMANS; KETOCONAZOLE; MALE; MIDDLE AGED; PHENOTYPE;

EID: 0141706469     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-003-0627-x     Document Type: Article

References (13)

1. Fogelman SM, Schmider J, Venkatakrishnan K, von Moltke LL, Harmatz JS, Shader RI, Greenblatt DJ (1999) O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology 20:480-490
2. Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM (1996) Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 41:149-156
3. Fukuda T, Nishida Y, Zhou Q, Yamamoto I, Kondo S, Azuma J (2000) The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population. Eur J Clin Pharmacol 56:175-180
4. Mahgoub A, Idle JR, Dring DG, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet 2:584-586
5. Skoda RC, Gonzalez FJ, Demierre A, Meyer UA (1988) Two mutant alleles of the human cytochrome P450 dbl gene (P450,II, D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci U S A 85:5240-5243
6. Heim M, Meyer UA (1990) Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336:529-532
7. Dahl ML, Johansson I, Porsmyr-Palmertz M, Ingelman-Sundberg M, Sjöqvist F (1992) Analysis of the CYP2D6 gene in relation to debrisoquine and desipramine hydroxylation in Swedish population. Clin Pharmacol Ther 51:12-17
8. Veefkind AH, Haffmans PM, Hoencamp E (2000) Venlafaxine serum levels and CYP2D6 genotype. Ther Drug Monit 22:202-208
9. Lessard E, Yessine MA, Hamelin BA, O'Hara G, LeBlanc J, Turgeon J (1999) Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics 9:435-443
10. Johansson I, Lundqvist E, Bertilsson L, Dahl M-L, Sjöqvist F, Ingelman-Sundberg M (1993) Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A 90:11825-11829
11. Böttiger Y, Tybring G, Götharsson E, Bertilsson L (1997) Inhibition of the sulphoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 62:384-391
12. Riley CM, James MO (1986) Determination of ketoconazole in plasma, liver, lung and adrenal of the rat by high-performance liquid chromatography. J Chromatogr 377:287-294
13. WinNonlin reference guide, Version 3.0. 1998-1999 Pharsight Corporation, Mountain view, CA, USA